Nicotinamide in dermatology

Expert Review of Dermatology

Volumn 5, Issue 1, 2010, Pages 23-29

  Kim, Nancy H ^a   Kirsner, Robert S ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Immunosuppression; Niacinamide; Nicotinamide; Sunscreen

Indexed keywords

1 METHYLNICOTINAMIDE; METHOTREXATE; NICOTINAMIDE; PLACEBO; TETRACYCLINE;

ACNE; ACNE VULGARIS; ANTIINFLAMMATORY ACTIVITY; BASAL CELL CARCINOMA; BULLOUS PEMPHIGOID; BULLOUS SKIN DISEASE; BURNING SENSATION; CONTACT DERMATITIS; DERMATOLOGY; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; ERYTHEMA; HUMAN; HYPERPIGMENTATION; IMMUNE DEFICIENCY; LIVER TOXICITY; NONHUMAN; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; PROPHYLAXIS; PSORIATIC ARTHRITIS; REVIEW; ROSACEA; SKIN IRRITATION; SKIN REDNESS; SKIN WATER LOSS; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET RADIATION;

EID: 77951638970     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/edm.09.68     Document Type: Review

References (53)

1. Gehring W. Nicotinic acid/niacinamide and the skin. J. Cosmet. Dermatol. 3(2), 88-93 (2004).
2. Damian D, Patterson C, Stapelberg M et al. UV radiation-induced immunosuppression is greater in men and prevented by topical nicotinamide. J. Invest. Dermatol. 128 (2), 447-454 (2008).
3. Yiasemides E, Sivapirabu G, Halliday GM et al. Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans. Carcinogenesis 30(1), 101-105 (2009).
4. Niggli HJ, Rothlisberger R. Cyclobutane-type pyrimidine photodimer formation and induction of ornithine decarboxylase in human skin fbroblasts after UV irradiation. J. Invest. Dermatol. 91(6), 579-584 (1988).
5. Keyse S, Tyrrell R. Induction of the heme oxygenase gene in human skin fbroblasts by hydrogen peroxide and UVA (365 nm) radiation; evidence for the involvement of the hydroxyl radical. Carcinogenesis 11(5), 787-791 (1990).
6. Hersey P, Bradley M, Hasic E et al. Immunological effects of solarium exposure. Lancet 1(8324), 545-548 (1983).
7. Kelly DA, Young AR, McGregor JM et al. Sensitivity to sunburn is associated with susceptibility to ultraviolet radiation-induced suppression of cutaneous cell-mediated immunity. J. Exp. Med. 191(3), 561-566 (2000).
8. Fisher M, Kripke M. Systemic alteration induced in mice by ultraviolet irradiation and its relationship to ultraviolet carcinogenesis. Proc. Natl Acad. Sci. USA 74(4), 1688-1690 (1977).
9. De Fabo EC, Kripke ML. Dose-response characteristics of immunologic unresponsiveness to UV-induced tumors produced by the UV irradiation of mice. Photochem. Photobiol. 30(3), 385-390 (1979).
10. De Fabo EC, Kripke ML. Wavelength dependence and dose-rate independence of UV radiation induced suppression of immunologic unresponsiveness of mice to a UV-induced fbrosarcoma. Photochem. Photobiol. 32, 183-188 (1980).
11. Marshall V. Premalignant and malignant skin tumours in immunosuppressed patients. Transplantation 17(3), 272-275 (1974).
12. Noonan FP, Muller HK, Fears TR et al. Mice with genetically determined high susceptibility to ultraviolet (UV)-induced immunosuppression show enhanced UV carcinogenesis. J. Invest. Dermatol. 121(5), 1176-1181 (2003).
13. Streilein JW, Taylor JR, Vincek V et al. Relationship between ultraviolet radiation-induced immunosuppression and carcinogenesis. J. Invest. Dermatol. 103(5 Suppl.), 107S-111S (1994).
14. Friedmann AC, Halliday GM, Barnetson RS et al. The topical isofavonoid NV-07a reduces solar-stimualated UV-induced suppression of Mantoux reactions in humans. Photochem. Photobiol. 80(3), 416-421 (2004).
15. Gensler HL. Prevention of immunosuppression and photocarcinogenesis by topical nicotinamide. Nutr. Cancer 29(2), 157-162 (1997).
16. Gensler HL, Williams T, Huang AC et al. Oral niacin prevents photocarcinogensis and photoimunosuppression in mice. Nutr. Cancer 34(1), 36-41 (1999).
17. Virag L, Szabo C. The therapeutic potential of poly (ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 54(3), 375-429 (2002).
18. Kosmadeki MG, Gilchrest BA. The role of telomeres in skin aging/photoaging. Micron 35(3), 155-159 (2004).
19. Sivapirabu G, Yiasemides E, Halliday GM, Park J, Damian DL. Topical nicotinamide modulates cellular energy metabolism and provides broad-spectrum protection against ultraviolet radiation-induced immunosuppression in humans. Br. J. Dermatol. 161(6), 1357-1364 (2009).
20. Poon TS, Barnetson RS, Halliday GM. Prevention of immunosuppression by sunscreens in humans is unrelated to protection from erythema and dependent on protection from ultraviolet A in the face of constant ultraviolet B protection. J. Invest. Dermatol. 121(1), 184-190 (2003).
21. Katiyar SK. UV-induced Immune Suppression and Photocarcinogenesis: Chemoprevention by Dietary Botanical Agents. Cancer Lett. 255(1), 1-11(2007).
22. Sharma SD, Katiyar SK. Dietary grape-seed proanthocyanidin inhibition of ultraviolet B-induced immune suppression is associated with induction of IL-12. Carcinogenesis 27(1), 95-102 (2006).
23. Moison RM, Beijersbergen Van Henegouwen GM Dietary eicosapentanoic acid prevents systemic immunosuppression in mice induced by UVB radiation. Radiat Res. 156, 36-44 (2001).
24. Kohler IK, Lorincz AL. Erythema Elevatum Diutinum Treated with Niacinamide and Tetracycline. Arch Dermatol. 116(6), 693-695 (1980).
25. Chaffns ML, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J. Am. Acad. Dermatol. 28(6), 998-1000 (1993).
26. Reiche L, Wojnarowska F, Mallon E. Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its effcacy. Clin. Exp. Dermatol. 23(6), 254-257 (1998).
27. Chaidemenos GC. Tetracycline and nicotinamide in the treatment of blistering skin diseases. Clin. Dermatol. 19(6), 781-785 (2001).
28. Fivenson DP, Kimbrough TL. Lichen planus pemphigoides: combination therapy with tetracycline and nicotinamide. J. Am. Acad. Dermatol. 36(4), 638-640 (1997).
29. Kolbach DN, Remme JJ, Bos WH. Bullous pemphigoid successfully controlled by tetracycline and nicotinamide. Br. J. Dermatol. 133(1), 88-90 (1995).
30. Namazi MR Nicotinamide: a potential addition to the antipsoriatic weaponry. FASEB J. 17(11), 1377-1379 (2003).
31. Bissett DL, Oblong JE, Berge CA. Niacinamide: a B vitamin that improves aging facial skin appearance. Dermatol. Surg. 31(7 Pt 2), 860-865 (2005).
32. Vlassara H. Recent progresson the biologic and clinical signifcance of advanced glycosylation end products. J. Lab. Clin. Med. 124(1), 19-30 (1994).
33. Wu JT. Advanced glycosylation end products: a new disease marker for diabetes and aging. J. Clin. Lab. Anal. 7(10), 252-255 (1993).
34. Wolff SP, Jiang ZY, Hung JV. Protein glycation and oxidative stress in diabetes mellitus and aging. Free Radic. Biol. Med. 10(3), 339-352 (1991).
35. Dyer DG, Dunn JA, Thorpe SR et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J. Clin. Invest. 91(6), 2463-2469 (1993).
36. Odetti P, Pronzato MA, Noberasco G et al. Relationships between glycation and oxidation related fuorescence in rat collagen during aging. Lab. Invest. 70(1), 61-67 (1994).
37. Reber F, Geffarth R, Kasper M et al. Graded sensitiveness of the various retinal neuron populations on the glyoxal-mediated formation of advanced glycation end products and ways of protection. Graefes Arch. Clin. Exp. Ophthalmol. 241(3), 213-215 (2003).
38. Thornalley PJ. Glycation in diabetic neuropathy: characteristics consequences, causes, and therapeutic options. Int. Rev. Neurobiol. 50, 37-57 (2002).
39. Matts PJ, Oblong JE, Bissett DL. A review of the range of effects of niacinamide in human skin. Int. Fed. Soc. Cosmet. Chem. Mag. 24(Suppl. 5), 285-289 (2002).
40. Varani J, Fisher GJ, Kang S et al. Molecular mechanisms of intrinsic skin aging and retinoid-induced repair and reversal. J. Invest. Dermatol. Symp. Proc. 3(1), 57-60 (1998).
41. Kang S, Duell EA, Fisher GJ et al. Application of retinol to human skin in vivo induces epidermal hyperplasia and cellular retinoid binding proteins characteristic of retinoic acid but without measurable retinoic acid levels of irritation. J. Invest. Dermatol. 105(4), 549-556 (1995).
42. Kligman AM, Baker TJ, Gordan HL. Long-term histologic follow-up of phenol face peels. Plast. Reconstr. Surg. 75(5), 652-659 (1975).
43. Hannon DP. Wrinkle effacement by chemical peel. Poster presentation at: Meeting of the American Academy of Dermatology, Dallas, TX, USA, December 1991.
44. Schwartz E, Kligman LH. Topical tretinoin increases the tropoelastin and fbronectin content of photoaged hairless mouse skin. J. Invest. Dermatol. 104(4), 518-522 (1995).
45. Gebicki J, Sysa-Jedrzejowska A, Adamus J et al. 1-Methylnicotinamide, a potent anti-infammatory agent of vitamin origin. Pol. J. Pharmacol. 44(1), 109-112 (2003).
46. Wozniacka M, Wiecorkowska M, Gebicki J, Sysa-Jedrzejowska A. Topical application of 1-methylnicotinamide in the treatment of rosacea: a pilot study. Clin. Exp. Dermatol. 30(6), 632-635 (2005).
47. Draelos ZD, Matsubara A, Smiles K. The effect of 2% niacinamide on facial sebum production. J. Cosmet. Laser Ther. 8(2), 96-101 (2006).
48. Jacobsen EL, Kim H, Kim M et al. A topical lipophilic niacin derivative increases NAD, epidermal differentiation and barrier function in photodamaged skin. Exp. Dermatol. 16(6), 490-499 (2007).
49. Ungerstedt JS, Blomback M, Soderstrom T. Nicotinamide is a potent inhibitor of proinfammatory cytokines. Clin. Exp. Immunol. 131(1), 48-52 (2003).
50. Rawlings AV, Matts PJ. Stratum corneum at the molecular level: an updated in relation to the dry skin cycle. J. Invest. Dermatol. 124(6), 1099-1110 (2005).
51. Draelos ZD, Ertel K, Hartwig P et al. Niacinamide-containing facial moisturizer improves skin barrier and benefts subjects with rosacea. Cutis 76(2), 135-141 (2005).
52. .. 147(1), 20-31 (2002).
53. Dunstan RW, Kennis RA. Selected heritable diseases of domesticated animals. In: Handbook of mouse mutations with skin and hair abnormalities. Sundberg JP (Ed.). CRC Press, Boca Raton, FL, USA, 509-532 (1994).